Ask about this productRelated genes to: PSMB2 antibody
- Gene:
- PSMB2 NIH gene
- Name:
- proteasome subunit beta 2
- Previous symbol:
- -
- Synonyms:
- HC7-I
- Chromosome:
- 1p34.3
- Locus Type:
- gene with protein product
- Date approved:
- 1995-05-03
- Date modifiied:
- 2016-10-05
Related products to: PSMB2 antibody
Related articles to: PSMB2 antibody
- Triple-negative breast cancer (TNBC) represents one of the most aggressive and therapeutically challenging subtypes of breast cancer, characterized by the absence of estrogen receptor, progesterone receptor, and HER2 expression. Due to the lack of specific molecular targets, treatment options for TNBC remain limited, resulting in higher recurrence rates, increased metastatic potential, and poorer overall survival compared with other breast cancer subtypes. Therefore, identifying novel therapeutic targets and potential bioactive compounds is essential for improving TNBC management. In this study, an integrative systems biology and computational pharmacology approach was employed to explore potential molecular targets underlying oxidative stress-mediated mechanisms in TNBC and to identify plant-derived compounds with therapeutic relevance. Transcriptomic analysis was performed to identify differentially expressed genes between TNBC and normal ductal tissues, followed by weighted gene coexpression network analysis to detect disease-associated gene modules. Intersection analysis integrating phytochemical targets, oxidative stress-related genes, and network-derived candidate genes identified seven potential key genes. Functional enrichment analysis revealed that these genes were mainly involved in oxidative stress response, DNA repair mechanisms, proteasome activity, and cell cycle regulation pathways. Immune infiltration analysis further demonstrated significant remodeling of the tumor immune microenvironment in TNBC. Machine learning algorithms identified PSMB2 as the most robust core gene associated with TNBC. Finally, molecular docking analysis demonstrated favorable binding interactions between the predicted target protein and several phytochemical compounds, particularly 6-gingerol, curcumin, and demethoxycurcumin. These findings highlight the potential of integrating computational approaches with natural product screening to identify novel therapeutic strategies for TNBC. - Source: PubMed
Publication date: 2026/08/21
Alshabrmi Fahad M - Glioblastoma multiforme (GBM), a highly aggressive primary brain malignancy, is characterized by its accelerated development, refractoriness to therapy, and dismal prognosis. The proteasome subunit β2 (PSMB2), a catalytic unit of the 20S proteasome, has been linked to tumorigenesis across multiple malignancies; however, its signaling and therapeutic relevance in GBM remains incompletely defined. U87 and U251 GBM cells were engineered to overexpress (OE-PSMB2) or silence (Sh-PSMB2) PSMB2. We assessed the function of PSMB2 in GBM cell proliferation, migration, and related phenotypes, and further examined its association with the PTEN/PI3K/AKT signaling axis at both transcriptomic and protein levels. A xenograft model was conducted in the intracranial setting where the therapeutic efficacy of PSMB2 silencing, when used together with temozolomide (TMZ), was assessed. PSMB2 overexpression stimulated GBM cell proliferation, migration, and invasion, and PSMB2 silencing inhibited these phenotypes and promoted apoptosis. RNA-seq showed that PI3K/AKT pathway was enriched in Sh-PSMB2 cells. Protein-level analysis showed that PSMB2 expression was inversely associated with PTEN abundance and was accompanied by altered PI3K/AKT pathway activity. PSMB2 silencing decreased tumor burden and increased survival in vivo, and the combination of PSMB2 silencing and TMZ produced the greatest therapeutic effect. PSMB2 may function as a tumor-promoting regulator in GBM and is associated with PTEN/PI3K/AKT pathway modulation. Targeting PSMB2 suppressed tumor progression and enhanced the therapeutic response to TMZ in vivo, suggesting that PSMB2 may represent a potential therapeutic target for GBM. - Source: PubMed
Publication date: 2026/07/20
Tan ZiLongTang XiaolongChen ZhuoZhong YutingYe QinglinLi MinHe Wei - Sepsis is a life-threatening systemic inflammatory syndrome with limited targeted therapeutic options. Handelin, a natural compound derived from Chrysanthemum indicum, exhibits anti-inflammatory activity, yet its direct targets and protective mechanisms in sepsis remain unclear. - Source: PubMed
Publication date: 2026/03/19
Chen DexiuZhang QianWu YuanxinHu YingchunChen Muhu - Neddylation modifications in immune and tumor cells are linked to poor tumor prognosis. This study identifies prognostic genes associated with neddylation-related genes (NRGs) in colorectal cancer (CRC) using single-cell and spatial transcriptome (ST) sequencing, aiming to advance CRC treatment strategies. - Source: PubMed
Publication date: 2025/12/24
Zhu ZimingZhang XinyueWang SongHuang YunsiHan XuedongLai DongpingYao XinLan WeixuanNong HuiZeng WenbinMo YanhuaXu Ri'anZhang Tao - Nasopharyngeal carcinoma (NPC), highly prevalent in southern China, often leads to treatment failure in advanced stages due to recurrence or metastasis. While METTL14 plays a crucial role in cancer, its regulation of immune- and inflammation-related genes remains poorly understood. This study aims to investigate whether METTL14 is involved in regulating the expression of genes associated with tumor necrosis factor (TNF), interferon (IFN), interleukin (IL), and MHC class I in NPC cells. - Source: PubMed
Zhou ZhihaoWang JingShen LingjunHan LiuxinLi QiwenWu AibingLi JingLiang ZumingZhu LitongHe DanhuaZhou YingHuang ShihaoZhao ZhanlinCong JingePeng ZhitaoZhao PingYe ShunaBai BinyiHong XuanjiaDai GuanqiLei YeZhao WentaoJia JunshuangLin XiaolinXiao DongZhang YuqinLin Taoyan